About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Systemic Diseases group performs translational research based on at least 300 patients with systemic lupus erytomatosus (SLE), antiphospholipid syndrome (APS), systemic sclerosis, vasculitis, dermatomyitis, Sjörgen syndrome or autoinflammatory syndromes in order to better understand their pathogenesis (both at the immunological and genetic regulation level), study their clinical and biological expression (through the detection of new markers that help characterize each of the autoimmune diseases), study morbimortality (through epidemiological studies) and analyse patients' response to medications. With these goals in mind, we seek to improve the diagnosis, clinical monitoring, and prognosis of our patients.
Cardiac involvement is one of the most serious internal organ involvements and the leading cause of death in SSc patients. The prevalence is 14% by clinical observation and even higher by autopsy Many SSc patients with cardiac involvement are asymptomatic or underdiagnosed. The condition may progress silently to overt clinical manifestations, including systolic and/or diastolic dysfunction, myocardial ischaemia, myocardial hypertrophy, heart failure, pericardial effusion and arrhythmias. Early detection of cardiac abnormalities is therefore very important. We evaluate cardiac involvement by echocardiography, MR, SPECT, and coronary CT.
IP: Carmen Pilar Simeón i Aznar, Vicenç Fonollosa Pla
We are currently enrolled in this multicentre study to investigate the possible influence of the genetic background in the disease pathogenesis, and to try to establish links between genetic variations and different clinical and biological patterns. The research is led by Prof. Javier Martín from the "Instituto López-Neyra" of Parasitology, CSIC (Granada). We contribute by sending samples from our cohort of patients along with the clinical data, and reviewing the results. It is supported by a SAS grant.
IP: Roser Solans Laque
With this study we aim to investigate the genetic background of the disease, to deepen in its pathogenesis and to be able to establish links between genetic variations and different clinic and biologic patterns. This research is based on a multicentric study and it is led by Prof. Javier Martín from the "Instituto López-Neyra" of Parasitology, CSIC (Granada). We contribute by sending samples from our cohort of patients along with the clinical data, and reviewing the results.
With this study we aim at studying the genetic background of the disease to deepen in its pathogenesis to be able to establish links between genetic variations and different clinic-biologic patterns. This research is based on a multicentric study and it is led by Prof. Javier Martín from the "Instituto López-Neyra" of Parasitology, CSIC (Granada). We contribute to it by sending samples from our cohort of patients along with the clinical data.
The study describes the first documented case worldwide of hereditary angioedema transmission through assisted reproduction.
15 researchers from the Rheumatology, Systemic Diseases and the Physiology and Pathophysiology of the Digestive Tract groups gave around 25 presentations.
The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.
